An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• The subjects voluntarily joined the study and signed the Informed consent forms (ICF).
• Measurable disease, as defined by RECIST v1.1.
• The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.
• Life expectancy ≥ 12 weeks.
Locations
Other Locations
China
Qilu Hospital of Shandong University
RECRUITING
Jinan
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Yuanchao Wang
yuanchao.wang@hengrui.com
0518-82342973
Time Frame
Start Date: 2025-03-13
Estimated Completion Date: 2027-12
Participants
Target number of participants: 300
Treatments
Experimental: SHR-A1811 group
Active_comparator: Chemotherapy group
Related Therapeutic Areas
Sponsors
Leads: Jiangsu HengRui Medicine Co., Ltd.